WilmerHale Counsels TransMedics in Closing of $51.2M Growth Financing to Transform Organ Transplant Therapy

WilmerHale Counsels TransMedics in Closing of $51.2M Growth Financing to Transform Organ Transplant Therapy

Firm News

TransMedics, Inc., a medical technology company dedicated to improving quality, assessing viability and increasing the utilization of donor organs for transplantation announced the closing of $51.2 million growth equity financing.

TransMedics has developed the Organ Care System (OCS™), a revolutionary first-in-class technology and multi-organ platform with the potential to improve outcomes for transplant patients and to dramatically increase the number of transplantable organs worldwide. The OCS™ is the only fully portable technology that maintains donor organs in a near-physiologic state outside of the human body and addresses the current limitations of cold storage.

The WilmerHale team on the transaction was led by Partner Rosemary Reilly and included Counsel Peter Osborn and Associate Byron Crowe.

Read TransMedics press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.